Literature DB >> 32349967

Sex Differences in Cancer Incidence and Survival: A Pan-Cancer Analysis.

Michelle Dong1, Gino Cioffi2,3,4,5, Jacqueline Wang4, Kristin A Waite2,3,4,5, Quinn T Ostrom5,6, Carol Kruchko5, Justin D Lathia7,8, Joshua B Rubin9, Michael E Berens10, James Connor11, Jill S Barnholtz-Sloan12,3,4,5,7,13,14.   

Abstract

BACKGROUND: Sex plays an important role in the incidence, prognosis, and mortality of cancers, but often is not considered in disease treatment.
METHODS: We quantified sex differences in cancer incidence using the United States Cancer Statistics (USCS) public use database and sex differences in cancer survival using Surveillance, Epidemiology, and End Results (SEER) public use data from 2001 to 2016. Age-adjusted male-to-female incidence rate ratios (IRR) with 95% confidence intervals (CI) were generated by primary cancer site, race, and age groups. In addition, age-adjusted hazard ratios with 95% CI by sex within site were generated.
RESULTS: In general, cancer incidence and overall survival were lower in males than females, with Kaposi sarcoma (IRR: 9.751; 95% CI, 9.287-10.242; P < 0.001) having highest male-to-female incidence, and thyroid cancers (HR, 1.774; 95% CI, 1.707-1.845) having largest male-to-female survival difference. Asian or Pacific Islanders had particularly high male-to-female incidence in larynx cancers (IRR: 8.199; 95% CI, 7.203-9.363; P < 0.001), relative to other races. Among primary brain tumors, germ cell tumors had the largest male-to-female incidence (IRR: 3.03; 95% CI, 2.798-3.284, P < 0.001).
CONCLUSIONS: Overall, incidence and survival of cancer vary significantly by sex, with males generally having lower incidence and survival compared with females. Male-to-female incidence differences were also noted across race and age groups. These results provide strong evidence that the fundamental biology of sex differences affects cancers of all types. IMPACT: This study represents the most recent and comprehensive reporting of sex differences in cancer incidence and survival in the United States. Identifying disadvantaged groups is critical as it can provide useful information to improve cancer survival, as well as to better understand the etiology and pathogenesis of specific cancers. ©2020 American Association for Cancer Research.

Entities:  

Year:  2020        PMID: 32349967     DOI: 10.1158/1055-9965.EPI-20-0036

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  24 in total

Review 1.  Sex-Specific Cardiovascular Risks of Cancer and Its Therapies.

Authors:  Nicholas S Wilcox; Seth J Rotz; McKay Mullen; Evelyn J Song; Betty Ky Hamilton; Javid Moslehi; Saro H Armenian; Joseph C Wu; June-Wha Rhee; Bonnie Ky
Journal:  Circ Res       Date:  2022-02-17       Impact factor: 17.367

Review 2.  The spectrum of sex differences in cancer.

Authors:  Joshua B Rubin
Journal:  Trends Cancer       Date:  2022-02-18

3.  Racial/ethnic and sex differences in young adult malignant brain tumor incidence by histologic type.

Authors:  Pablo Monterroso; Kristin J Moore; Jeannette M Sample; Natali Sorajja; Allison Domingues; Lindsay A Williams
Journal:  Cancer Epidemiol       Date:  2021-12-09       Impact factor: 2.984

4.  Epidemiology of pineoblastoma in the United States, 2000-2017.

Authors:  Kaitlyn Greppin; Gino Cioffi; Kristin A Waite; Quinn T Ostrom; Daniel Landi; Kailey Takaoka; Carol Kruchko; Jill S Barnholtz-Sloan
Journal:  Neurooncol Pract       Date:  2022-01-27

5.  Sex- and Gender-Based Pharmacological Response to Drugs.

Authors:  Franck Mauvais-Jarvis; Heiner K Berthold; Ilaria Campesi; Juan-Jesus Carrero; Santosh Dakal; Flavia Franconi; Ioanna Gouni-Berthold; Mark L Heiman; Alexandra Kautzky-Willer; Sabra L Klein; Anne Murphy; Vera Regitz-Zagrosek; Karen Reue; Joshua B Rubin
Journal:  Pharmacol Rev       Date:  2021-04       Impact factor: 25.468

6.  An updated histology recode for the analysis of primary malignant and nonmalignant brain and other central nervous system tumors in the Surveillance, Epidemiology, and End Results Program.

Authors:  Gonçalo Forjaz; Jill S Barnholtz-Sloan; Carol Kruchko; Rebecca Siegel; Serban Negoita; Quinn T Ostrom; Lois Dickie; Jennifer Ruhl; Alison Van Dyke; Nirav Patil; Gino Cioffi; Kimberly D Miller; Kristin Waite; Angela B Mariotto
Journal:  Neurooncol Adv       Date:  2020-12-08

7.  Sex Differences in Time to Treat and Outcomes for Gliomas.

Authors:  Nickolas Stabellini; Halle Krebs; Nirav Patil; Kristin Waite; Jill S Barnholtz-Sloan
Journal:  Front Oncol       Date:  2021-02-19       Impact factor: 6.244

8.  Type 2 diabetes is more predictable in women than men by multiple anthropometric and biochemical measures.

Authors:  Tangying Li; Huibiao Quan; Huachuan Zhang; Leweihua Lin; Lu Lin; Qianying Ou; Kaining Chen
Journal:  Sci Rep       Date:  2021-03-15       Impact factor: 4.379

9.  Computational Identification of Sex-Biased Biomarker MicroRNAs and Genes Associated with Immune Infiltration in Breast Cancer.

Authors:  Eric W Li; Yongsheng Bai
Journal:  Genes (Basel)       Date:  2021-04-14       Impact factor: 4.096

10.  Brd4-bound enhancers drive cell-intrinsic sex differences in glioblastoma.

Authors:  Najla Kfoury; Zongtai Qi; Briana C Prager; Michael N Wilkinson; Lauren Broestl; Kristopher C Berrett; Arnav Moudgil; Sumithra Sankararaman; Xuhua Chen; Jason Gertz; Jeremy N Rich; Robi D Mitra; Joshua B Rubin
Journal:  Proc Natl Acad Sci U S A       Date:  2021-04-20       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.